Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
keverprazan hydrochloride
- Development stage
- Unknown
- Lead developer
- Carephar
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Keverprazan hydrochloride (formerly known as caprazan hydrochloride) is a potassium-competitive acid blocker (P-CAB) developed by Jiangsu Carephar Pharmaceutical. It acts by reversibly inhibiting the gastric H+/K+-ATPase (proton pump) in a potassium-competitive manner, providing rapid and sustained suppression of gastric acid secretion. Unlike traditional proton pump inhibitors (PPIs), P-CABs do not require acid activation and can inhibit both active and resting proton pumps, leading to a faster onset of action and more consistent acid control. Keverprazan was approved by the China National Medical Products Administration (NMPA) in 2023 for the treatment of duodenal ulcers and has since been approved for erosive esophagitis (reflux esophagitis). It is also being evaluated in specific populations, including patients with renal insufficiency, to determine appropriate dosing and safety profiles.
- Brand names
- Kewei
- Other names
- caprazan hydrochloridecaprazankeverprazan
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)KCNH2 (Voltage-gated potassium channel subfamily H member 2)
Beyond the preview
Go deeper on keverprazan hydrochloride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on keverprazan hydrochloride.